Find a CGM Inserter To Perform Eversense Procedures | Insertion & Removal ProceduresE3 Safety Information | Eversense CGM
Owner's Manual for eversense models including: E3 Approves 6 Month Sensor, E3, Approves 6 Month Sensor, 6 Month Sensor, Month Sensor, Sensor
Eversense Glucose Monitoring (CGM) Diabetes System Designed to Fit Your Lifestyle
CGM Device With Long-Lasting 6 Month Sensor & Removable Transmitter | Eversense E3
File Info : application/pdf, 2 Pages, 365.01KB
DocumentDocumentDISCUSSION GUIDE Manage Diabetes. Not CGM LIMITATIONS. If you're experiencing any of the following frustrations with your current CGM, bring this form to your next appointment and start the conversation with your doctor about how Eversense E3 may be a better fit for your diabetes management plan. Problem Constant self-insertions/sensor changes and disruptions to everyday life. Sensor failing before it's replacement date wasting you time and money. The unexpected disruptions from sensors falling out or being knocked off. False lows or alerts due to false readings. Audible alerts that are disruptive or causing fatigue. Painful or itchy skin reactions from aggressive adhesives. EversenseE3 Solution No need for frequent sensor changes. Less to manage with only one sensor insertion and warm-up period every 6 months. Unlike the every 7-14 days with short-term CGM systems. Fewer failed or wasted sensors.1-4 Each 6-month sensor has high survivability so fewer wasted sensors. Flexible wear, to fit into your life. Easy-on, easy-off smart transmitter* allows you to take short, infrequent breaks when you need it. *No readings generated when transmitter is removed Alerts you can trust. Get exceptional accuracy5 with 99% of high and 94% of low glucose events detected correctly and essentially no compression lows.1,-9 Improved discretion. The only CGM with on-body vibration alerts that notify you if your glucose is high or low. Now you can receive notifications even without your phone nearby, or anytime you want added discretion. Less skin irritation, more comfort. Mild, silicone-based adhesives are changed daily and cause almost no skin reactions.8 PRINT THIS GUIDE FOR YOUR NEXT APPOINTMENT EversenseCGM.com Your Patients Desee to Live Life UNINT RUPTED. If your patients are experiencing CGM disruption due to device malfunction, sensor insertion problems or sensors falling off, it's time to get them set up with Eversense E3. INFORMATION FOR DOCTORS #1 CGM in Suivability and Longevity1-5 Eversense E3 is the only long lasting 6-month sensor that reduces the burden of frequent short-term sensor failures. Most Accurate in Low Glucose Ranges 1-9 Patented Fluorescent Technology delivers the highest accuracy in critical low glucose ranges with essentially no compression lows. Most Dependable Detection Alerts1-9 Eversense E3 delivers exceptional accuracy for the entire 6 months of wear time with only 1 insertion and 1 "day one." Almost no skin reactions from adhesive 8 Less than 1% of Eversense E3 users experience skin reactions caused by the mild silicone-based adhesives that are changed daily. Help your patients make the switch to Eversense. Find a nearby proceduralist for your patients Go to bit.ly/eversense-find-provider or contact us at 1-844-SENSE4U (1-844-736-7348) © 2024 Senseonics, Inc. All rights reserved. © 2024 Ascensia Diabetes Care Holdings AG. All rights reserved. Distrubuted by Ascensia Diabetes Care 5 Wood Hollow Road Parsippany, NJ 07054 844-SENSE4U (736-7348) ascensiadiabetes.com/eversense Manufactured by Senseonics, Inc. 20451 Seneca Meadows Parkway Germantown, MD 20876-7005 USA The Eversense E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For safety information, see bit.ly/eversensesafety Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. Android is a trademark of Google LLC. Apple Watch is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense E3 CGM System. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied. PP-SENS-E3-GBL-0032 1. Abbott. (2020) FreeStyle Libre 2 Flash Glucose Monitoring System User Manual. ART40703-001 Rev. D 06/20 2. Abbott. (2022) FreeStyle Libre 3 Flash Glucose Monitoring System User Manual. ART43911-001 Rev. B 06/22 3. Medtronic. (2020) Guardian Connect System User Guide. 2020-Rev M995836A012_A 4. Dexcom. (2023) G7 User Guide. AW00078-10 Rev 002 MT-00078-10 5. Senseonics. (2023) Eversense E3 Continuous Glucose Monitoring System User Guide. LBL-6002-01-001_Rev C 6. Data on File. Ascensia Diabetes Care. Eversense E3 CGM Real-World 7. Hanson, K. et al. (2024). Comparison of point accuracy between two widely used continuous glucose monitoring 8. Deiss, D. et al. (2020). Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. Diabetes Technology & Therapeutics, 22(1), 4852. 9. Garg (2022) Evaluation of Accuracy and Safety of the Next-Generation (PROMISE Study) - DTT (v0.1) - Table 4 -Overall MARD - 8.5% (CGM System Agreement to Reference w/in Yellow Springs Instrument Glucose Ranges Through180 Days (p.6) Garg (2022) Evaluation of Accuracy and Safety of the Next-Generation (PROMISE Study) - DTT (v0.1) -Clinically proven accurate through 6 months (p.1).